Abstract
The aggregation of α-synuclein (Syn or S) to form insoluble fibrils is important in the pathogenesis of Parkinson’s disease, but key risk factors remain ill-defined. We have developed Fluorescence Resonance Energy Transfer (FRET)-based assays for α-synuclein aggregation, using Green Fluorescent Protein variants Cerulean (C) or Venus (V), fused to each other (CV, VC) or to human synuclein (SC, SV etc). Bacterially expressed proteins were purified to homogeneity, and C-terminal fusions SC and SV largely retained their ability to aggregate in vitro. FRET signals from mixtures of SC and SV were used to monitor aggregation. These fusion genes were linked to the C. elegans unc-54 myosin promoter to generate integrated transgenic strains. Increased FRET signals, indicative of S aggregation, were observed following treatment of unc-54::SC + unc-54::SV double transgenic worms with low concentrations of mercury or chlorpyrifos, or with RNAi against hsp-70 and hip-1. Opposite changes in Yellow Fluorescent Protein (YFP) fluorescence in an unc-54::SV strain (NL5901) are likely to reflect FRET from Yellow Fluorescent Protein to aggregates of Syn fusion protein. This could provide the basis for a high throughput screening assay, which could be used for studying the effects of toxic chemicals and environmental pollutants on the aggregation of proteins such as Syn in vivo.
Keywords: FRET, C. elegans, α-synuclein, aggregation, pollutants, fluorescent proteins.
CNS & Neurological Disorders - Drug Targets
Title:A Fluorescence Resonance Energy Transfer Assay For Monitoring α- Synclein Aggregation in a Caenorhabditis Elegans Model For Parkinson’s Disease
Volume: 14 Issue: 8
Author(s): Archana Nagarajan, Rakesh Bodhicharla, Jody Winter, Charumathi Anbalagan, Kevin Morgan, Mark Searle, Aamir Nazir, Ademola Adenle, April Fineberg, Declan Brady, Kelly Vere, Jo Richens, Paul O'Shea, David Bell and David de-Pomerai
Affiliation:
Keywords: FRET, C. elegans, α-synuclein, aggregation, pollutants, fluorescent proteins.
Abstract: The aggregation of α-synuclein (Syn or S) to form insoluble fibrils is important in the pathogenesis of Parkinson’s disease, but key risk factors remain ill-defined. We have developed Fluorescence Resonance Energy Transfer (FRET)-based assays for α-synuclein aggregation, using Green Fluorescent Protein variants Cerulean (C) or Venus (V), fused to each other (CV, VC) or to human synuclein (SC, SV etc). Bacterially expressed proteins were purified to homogeneity, and C-terminal fusions SC and SV largely retained their ability to aggregate in vitro. FRET signals from mixtures of SC and SV were used to monitor aggregation. These fusion genes were linked to the C. elegans unc-54 myosin promoter to generate integrated transgenic strains. Increased FRET signals, indicative of S aggregation, were observed following treatment of unc-54::SC + unc-54::SV double transgenic worms with low concentrations of mercury or chlorpyrifos, or with RNAi against hsp-70 and hip-1. Opposite changes in Yellow Fluorescent Protein (YFP) fluorescence in an unc-54::SV strain (NL5901) are likely to reflect FRET from Yellow Fluorescent Protein to aggregates of Syn fusion protein. This could provide the basis for a high throughput screening assay, which could be used for studying the effects of toxic chemicals and environmental pollutants on the aggregation of proteins such as Syn in vivo.
Export Options
About this article
Cite this article as:
Nagarajan Archana, Bodhicharla Rakesh, Winter Jody, Anbalagan Charumathi, Morgan Kevin, Searle Mark, Nazir Aamir, Adenle Ademola, Fineberg April, Brady Declan, Vere Kelly, Richens Jo, O'Shea Paul, Bell David and de-Pomerai David, A Fluorescence Resonance Energy Transfer Assay For Monitoring α- Synclein Aggregation in a Caenorhabditis Elegans Model For Parkinson’s Disease, CNS & Neurological Disorders - Drug Targets 2015; 14 (8) . https://dx.doi.org/10.2174/1871527314666150821110538
DOI https://dx.doi.org/10.2174/1871527314666150821110538 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Preliminary X-Ray Study of a Refolded PTS EIIBfruc Protein from Escherichia coli
Protein & Peptide Letters Plasma Clusterin as a Potential Biomarker for Alzheimer’s Disease-A Systematic Review and Meta-analysis
Current Alzheimer Research Insulin Resistance, Glycemic Control and Adiposity: Key Determinants of Healthy Lifespan
Current Alzheimer Research From Substance Dependence to Addiction: Impact of a Conceptual Shift on Therapeutic Approaches?
Current Pharmaceutical Design Antiinflammatory Activity of Melatonin in Central Nervous System
Current Neuropharmacology Inhibitors of Catechol-O-Methyltransferase
CNS & Neurological Disorders - Drug Targets Role of Melatonin in the Inflammatory Process and its Therapeutic Potential
Current Pharmaceutical Design Editorial (Thematic Issue: Playing Well with Others! Initiating and Sustaining Successful Collaborations between Industry, Academia and Government)
Current Topics in Medicinal Chemistry Identifying the Structural Features of Pyrazolo[4,3-c]Quinoline-3-ones as Inhibitors of Phosphodiesterase 4: An Exploratory CoMFA and CoMSIA Study
Current Enzyme Inhibition Nanotechnology Applications for Diffuse Intrinsic Pontine Glioma
Current Neuropharmacology Reconstruction of the Network of Experimentally Validated AMP-Drug Combinations Against Pseudomonas aeruginosa Infections
Current Bioinformatics Chromosomal Micro-aberration in a Saudi Family with Juvenile Myoclonic Epilepsy
CNS & Neurological Disorders - Drug Targets Angiopoietin-1 and C16 Peptide Attenuate Vascular and Inflammatory Responses in Experimental Allergic Encephalomyelitis
CNS & Neurological Disorders - Drug Targets Biomedical Technologies for In Vitro Screening and Controlled Delivery of Neuroactive Compounds
Central Nervous System Agents in Medicinal Chemistry Foreword [Cannabinoid Special Issue (Guest Editor: Ruth A. Ross)]
Current Neuropharmacology ERRATUM
Current Neuropharmacology Statin-Like Drugs for the Treatment of Brain Cholesterol Loss in Alzheimers Disease
Current Drug Safety Role of the Innate Immune System in Autoimmune Inflammatory Demyelination
Current Medicinal Chemistry Current Options and Future Possibilities for the Treatment of Dyskinesia and Motor Fluctuations in Parkinson's Disease
CNS & Neurological Disorders - Drug Targets P-Glycoprotein - Implications of Metabolism of Neoplastic Cells and Cancer Therapy
Current Cancer Drug Targets